3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
HER2-positive Breast Cancer
4
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
Gemcitabine
6
Cisplatin
6
pembrolizumab
3
durvalumab
3
Oxaliplatin
3
tivozanib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
trametinib
1
tislelizumab
1
olaparib
1
atezolizumab
1
Yttrium-90
1
Stents
1
Radiosurgery
1
Nivolumab
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Floxuridine
1
Dexamethasone
1
Capecitabine
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
pertuzumab
×
90 days
×
Clear all
No trials found.